

Pruritus pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

<https://marketpublishers.com/r/P2BA48773808EN.html>

Date: July 2020

Pages: 189

Price: US\$ 1,599.00 (Single User License)

ID: P2BA48773808EN

Abstracts

2020 Pruritus PIPELINE HIGHLIGHTS

Pruritus is one of the widely researched conditions during 2020 with 38 companies actively focusing on realizing pipeline's potential. Development of Pruritus medicines is identified as integral to the strategy of the majority of companies operating in the industry.

Global Pruritus market presents promising new product pipeline with NME Projects, pivotal trials, and rapidly phase-advancing therapeutic candidates. Increasing number of companies are assessing the feasibility of developing treatment options for Pruritus.

Good progress is anticipated during 2020 and 2021 with Pruritus pipeline molecules advancing from pre-clinical investigation to completion of advanced Phase clinical trials. Pruritus pipeline continues to expand and progress with novel mechanisms and diverse routes of administration being tested by companies.

Pruritus DRUG DEVELOPMENT PIPELINE OVERVIEW

The "Pruritus pipeline Research Monitor, 2020" report is an analytical research study on the progress achieved by pipeline companies during the year along with its historical development, current status, and outlook.

This Pruritus pipeline review explores high-potential early to late-stage pipeline projects with a continued focus on new insights, accelerated processes, and pipeline progression.

The competitive intelligence report on Pruritus presents detailed insights into therapeutic drug pipeline development, industry news, deals, and analysis across the length and breadth of the Pruritus pipeline. Information on R&D pipeline updates, results of key clinical trials are also included in the report.

Pruritus DRUG PROFILES

Pruritus development pipeline including projects in early- and late-stage development are detailed in the report. Details of clinical trial data and submissions to regulatory authorities are also provided. For the drug candidates included in the report, the following information is provided-

Current Status of Development including phase advancements, regulatory approvals of phases, acquisitions, licensing and technology transfers, product launches in various markets, and others.

Phase of development

Mechanism of Action

Route of Administration

Companies involved including originator, licensing companies, developer, investors, and others

New molecular entity details

Orphan drug designation and other special status provided by regulators

Pruritus COMPANY PROFILES

Both small size and large size pharmaceutical companies are investing their resources in Pruritus drug development operations. Further, financial institutions are extending support to small pharmaceutical companies, universities, and other researchers for the development of treatment of Pruritus. Partnerships and acquisitions are also increasingly observed in the pipeline.

This research report presents an analysis of 38 Pruritus companies including company overview, key snapshot, contact information, and their strategies on accelerating Pruritus pipeline development. Mid-stage and early portfolios of these companies are analyzed in detail in the report.

Companies analyzed in the report include- Albireo Pharma Inc, Amgen Inc, AntalGenics SL, AOBiome LLC, Asana BioSciences LLC, Avior Bio Inc, BELLUS Health Inc,

Biomimetix JV LLC, Cara Therapeutics Inc, Chugai Pharmaceutical Co Ltd, DermaXon LLC, Eli Lilly and Co, ELORAC Inc, GlaxoSmithKline Plc, Hydra Biosciences Inc, Jiangsu Hengrui Medicine Co Ltd, Kiniksa Pharmaceuticals Corp, Lumosa Therapeutics Co Ltd, MC2 Therapeutics AS, Menlo Therapeutics Inc, Neurim Pharmaceuticals Ltd, Nocion Therapeutics, Patagonia Pharmaceuticals LLC , Peptide Logic, RDD Pharma Ltd, Roivant Sciences Ltd, Saniona AB, Sanwa Kagaku Kenkyusho Co Ltd, Shaperon Inc, Sienna Biopharmaceuticals Inc, Sumitomo Dainippon Pharma Co Ltd, Sunny Pharmtech Inc, Teikoku Pharma USA Inc, Tioga Pharmaceuticals Inc, Toray Industries Inc, Trevi Therapeutics Inc, Vanda Pharmaceuticals Inc, Vivozon Inc

REASONS TO BUY

The current market conditions are forcing companies and investors worldwide to prioritize their investments and accelerate pipeline candidates only through careful quantitative assessment.

This research work assists decision makers in pharmaceutical companies towards successful pipeline development through critically evaluated pipeline data

Buyers can identify most promising drug candidates for treatment of Pruritus

It allows users to strengthen their pipeline through acquisitions, licensing and collaborations

Users can estimate possible delays in the delivery of pipeline or launch of new products

Stay ahead of competition through understanding their pipeline progression, strategies and outlook

The report details all the pipeline candidates under investigation in various stages of development from Phase I through to Phase III to enable business development managers to understand the impact of new launches.

Optimize your licensing and technology transfer strategies through identification of prospect partners

Contents

1. INTRODUCTION TO PRURITUS

- 1.1 Pruritus- Disease overview
- 1.2 Pruritus- Market Size
- 1.3 Pruritus- Companies Involved

2. PRURITUS PIPELINE SNAPSHOT- 2020

- 2.1 Pruritus Pipeline by Phase
- 2.2 Pruritus Pipeline by Mechanism of Action
- 2.3 Pruritus Pipeline by Route of Administration
- 2.4 Pruritus Pipeline- New Molecular Entities
- 2.5 Pruritus Pipeline- Orphan Drug Designation/ Special Designation

3. PRURITUS DRUG PROFILES

- 3.1 Current Status
- 3.2 Pruritus Drug Snapshot
- 3.3 Pruritus Therapeutic Candidates- Originator/Licensors
- 3.4 Route of Administration
- 3.5 Mechanism of Action
- 3.6 NME
- 4.1 Albireo Pharma Inc Pruritus Pipeline Insights and Clinical Trials
- 4.2 Amgen Inc Pruritus Pipeline Insights and Clinical Trials
- 4.3 AntalGenics SL Pruritus Pipeline Insights and Clinical Trials
- 4.4 AOBiome LLC Pruritus Pipeline Insights and Clinical Trials
- 4.5 Asana BioSciences LLC Pruritus Pipeline Insights and Clinical Trials
- 4.6 Avior Bio Inc Pruritus Pipeline Insights and Clinical Trials
- 4.7 BELLUS Health Inc Pruritus Pipeline Insights and Clinical Trials
- 4.8 Biomimetix JV LLC Pruritus Pipeline Insights and Clinical Trials
- 4.9 Cara Therapeutics Inc Pruritus Pipeline Insights and Clinical Trials
- 4.10 Chugai Pharmaceutical Co Ltd Pruritus Pipeline Insights and Clinical Trials
- 4.11 DermaXon LLC Pruritus Pipeline Insights and Clinical Trials
- 4.12 Eli Lilly and Co Pruritus Pipeline Insights and Clinical Trials
- 4.13 ELORAC Inc Pruritus Pipeline Insights and Clinical Trials
- 4.14 GlaxoSmithKline Plc Pruritus Pipeline Insights and Clinical Trials
- 4.15 Hydra Biosciences Inc Pruritus Pipeline Insights and Clinical Trials

- 4.16 Jiangsu Hengrui Medicine Co Ltd Pruritus Pipeline Insights and Clinical Trials
- 4.17 Kiniksa Pharmaceuticals Corp Pruritus Pipeline Insights and Clinical Trials
- 4.18 Lumosa Therapeutics Co Ltd Pruritus Pipeline Insights and Clinical Trials
- 4.19 MC2 Therapeutics AS Pruritus Pipeline Insights and Clinical Trials
- 4.20 Menlo Therapeutics Inc Pruritus Pipeline Insights and Clinical Trials
- 4.21 Neurim Pharmaceuticals Ltd Pruritus Pipeline Insights and Clinical Trials
- 4.22 Nocion Therapeutics Pruritus Pipeline Insights and Clinical Trials
- 4.23 Patagonia Pharmaceuticals LLC Pruritus Pipeline Insights and Clinical Trials
- 4.24 Peptide Logic Pruritus Pipeline Insights and Clinical Trials
- 4.25 RDD Pharma Ltd Pruritus Pipeline Insights and Clinical Trials
- 4.26 Roivant Sciences Ltd Pruritus Pipeline Insights and Clinical Trials
- 4.27 Saniona AB Pruritus Pipeline Insights and Clinical Trials
- 4.28 Sanwa Kagaku Kenkyusho Co Ltd Pruritus Pipeline Insights and Clinical Trials
- 4.29 Shaperon Inc Pruritus Pipeline Insights and Clinical Trials
- 4.30 Sienna Biopharmaceuticals Inc Pruritus Pipeline Insights and Clinical Trials
- 4.31 Sumitomo Dainippon Pharma Co Ltd Pruritus Pipeline Insights and Clinical Trials
- 4.32 Sunny Pharmtech Inc Pruritus Pipeline Insights and Clinical Trials
- 4.33 Teikoku Pharma USA Inc Pruritus Pipeline Insights and Clinical Trials
- 4.34 Tioga Pharmaceuticals Inc Pruritus Pipeline Insights and Clinical Trials
- 4.35 Toray Industries Inc Pruritus Pipeline Insights and Clinical Trials
- 4.36 Trevi Therapeutics Inc Pruritus Pipeline Insights and Clinical Trials
- 4.37 Vanda Pharmaceuticals Inc Pruritus Pipeline Insights and Clinical Trials
- 4.38 Vivozon Inc Pruritus Pipeline Insights and Clinical Trials

5. PRURITUS MARKET NEWS AND UPDATES

6. APPENDIX

- 6.1 Sources and Methodology
- 6.2 Contact Information

I would like to order

Product name: Pruritus pipeline Research Monitor, 2020- Drugs, Companies, Clinical Trials, R&D pipeline updates, status and outlook

Product link: <https://marketpublishers.com/r/P2BA48773808EN.html>

Price: US\$ 1,599.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P2BA48773808EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

